Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic ...

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the ...

Myelodysplastic syndrome (MDS) is a puzzling, life-threatening set of disorders for which there are no easy cures or quick remedies. Symptoms can range from weakness and excessive bruising to ...

Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas Myelodysplastic syndrome (MDS) classification currently relies mainly on its morphologic features and ...

Somatic MDS mutations occur in five major categories, including RNA splicing, DNA methylation, activated cell signaling, myeloid transcription factors, and chromatin modifiers. Although many MDS cases ...

—Classifying myelodysplastic syndrome and secondary acute myeloid leukemia by genetic mutations rather than strictly by blast count may allow more patients to be eligible for AML and MDS clinical ...

Revlimid is showing promise for patients with low-risk MDS, according to the results of a recent study. Nearly 40 percent of patients with low intermediate-1 risk myelodysplastic syndrome (MDS) who ...